Edit
AAVantgarde Bio
https://www.aavantgardebio.com/Last activity: 08.11.2025
Probably Closed - Reference to AAVantgarde Bio
AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors
Location: Italy
Total raised: $141M
Investors 2
| Date | Name | Website |
| 18.06.2023 | Forbion | forbion.co... |
| 15.06.2023 | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.11.2025 | Series B | $141M | Sofinnova ... |
Mentions in press and media 10
| Date | Title | Description |
| 08.11.2025 | AAVantgarde Secures $141M for Groundbreaking Gene Therapies | AAVantgarde Bio closed a $141 million Series B round. This substantial funding propels gene therapy programs for inherited retinal diseases. Key targets: Stargardt disease and Usher Syndrome Type 1B. Both represent severe conditions with no... |
| 07.11.2025 | AAVantgarde: $141 Million Series B Closed To Advance Clinical Programs For Stargardt Disease And Usher 1B Syndrome | AAVantgarde Bio has closed a $141 million (€122 million) Series B financing to advance its lead clinical programs targeting inherited retinal diseases. The financing round was co-led by Schroders Capital, Atlas Venture, and Forbion, with pa... |
| 06.11.2025 | AAVantgarde Closes $141M Series B Financing | AAVantgarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing therapies for inherited retinal diseases (IRDs), raised $141M in Series B funding. The round was led by Schroders Capital, as well as existing investors ... |
| 12.08.2025 | AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease | MILAN, August 12, 2025 — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has gr... |
| 15.07.2025 | AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial | - AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutation - CELESTE is informed by the STELLA prospective natural history study, which is cur... |
| 02.12.2024 | AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa | December 2, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced that the U.S. ... |
| 03.05.2024 | AAVantgarde presents the design of its innovative LUCE-1 trial for USH1B at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit | May 3, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the presentation of... |
| 23.04.2024 | AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting | April 23, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the publication ... |
| 06.06.2023 | AAVantgarde Bio Closes €61M Series A Financing | AAVantagarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing two proprietary Adeno-Associated Viral (AAV) vector platforms, raised €61M in Series A funding. The round was co-led by Atlas Venture and Forbion, with ... |
| - | AAVantgarde Bio | “Homepage - AAVantgarde Bio” |